Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?

Launched by UNIVERSITY HOSPITAL CENTER OF MARTINIQUE · Aug 8, 2022

Keywords

ClinConnect Summary

The OBESICA study is a clinical trial that aims to explore whether eating pigeon peas, a legume known for its anti-inflammatory benefits, can help obese patients lose weight when combined with regular exercise. The trial is particularly focused on individuals with severe obesity, defined as having a body mass index (BMI) of 35 or higher. Researchers believe that reducing inflammation in the body may make it easier for these patients to lose weight, which can lower their risk of serious health problems.

To participate in this study, individuals must be female, between the ages of 65 and 74, and have a BMI of 35 or more. They should also be ready to follow a personalized exercise program for 24 weeks and commit to follow-up visits for up to 36 weeks. However, certain individuals will not be eligible, such as those who are pregnant, have specific medical conditions, or are taking certain medications that could interfere with weight loss. Participants can expect to consume pigeon peas regularly and engage in physical activity while being closely monitored by the research team.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Have a BMI ≥ 35 kg/m² (severely obese)
• • Ability, at the time of inclusion, to follow a personalized physical activity program for 24 weeks.
• • Have agreed to follow-up for up to 36 weeks
• • Be affiliated to a social security system
• • Be able to freely give informed consent (oral)
• Exclusion Criteria:
• • Pregnant woman
• • Have a history of type 1 diabetes
• • Weight \>150 kg (criterion related to the capacity of the exercise bikes used in the study)
• • History of renal disease \[glomerular filtration \< 30 mL/min\], cardiovascular history of myocardial ischemia (ECG signs), uncontrolled hypertension \[at rest; systolic blood pressure \> 140 mm Hg and diastolic blood pressure \> 90 mm Hg\], heart failure, cardiac valvulopathy, peripheral arterial disease or arteritis, and stroke.
• • Have an auto-inflammatory or autoimmune pathology known to modify the expression of NLRP3 (cryopyrinopathies, Crohn's disease, gouty arthritis, chondrocalcinosis, arthritic diseases, type 1 diabetes, Biermer's disease, Basedow's disease, rheumatoid arthritis, systemic lupus erythematosus, sclerodermias, non-alcoholic liver steatosis, multiple sclerosis, Alzheimer's and Parkinson's diseases)
• • Have a history of recent (\<6 months) infectious disease of viral, parasitic, fungal or bacterial origin known to modify the expression of NLRP3
• • Taking medication that may affect weight gain (systemic corticosteroids, psychotropic drugs, migraine medications, beta-blockers, chemotherapy, and antibiotics)
• • Have completed a personalized physical activity program in the 12 weeks prior to inclusion,
• • Have bariatric surgery scheduled within 6 months of inclusion,
• • Have a known intolerance to legume seeds
• • Have an unbalanced low-calorie diet
• • Have consumed dietary supplements containing polyphenols of the flavonoid class (green tea catechins and isoflavones from soy and legume seeds in the 3 months prior to inclusion).